J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A
Executive Summary
Johnson & Johnson has built a strong oncology business by making smart partnering plays. Now the company is looking to write a new chapter, building on its single-asset successes with a portfolio of new cancer drugs developed both internally and through more M&A.
You may also be interested in...
Janssen Oncology Strategy: Take A Holistic Approach To R&D
With Darzalex in the spotlight at the ASCO annual meeting, J&J highlights its comprehensive focus on trio of disease areas – hematology, prostate cancer and lung cancer.
J&J/Genmab’s Darzalex Leads Way For Anti-CD38 Antibodies in Myeloma
Speedy even by the standards of accelerated approval, FDA’s clearance of first-in-class daratumumab in salvage setting gives hope for broader ambitions in myeloma and beyond.
Deal Watch: Immuno-Oncology Collaborations Keep Piling Up
AstraZeneca and Genentech sign agreements with a number of firms with promising early stage assets, with Bristol looking to spread reach into rare cancers; J&J joins the game. Drama continues to unfold for Mylan/Perrigo, Shire/Baxalta and Horizon/Depomed.